23andMe Receives FDA 510(K) Clearance To Expand Its Existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report
Portfolio Pulse from Benzinga Newsdesk
23andMe has received FDA 510(K) clearance to expand its existing BRCA1/BRCA2 genetic health risk report. The clearance allows the company to report an additional 41 variants in the BRCA1 and BRCA2 genes associated with higher risk for certain types of cancer.
August 31, 2023 | 9:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
23andMe's FDA clearance to expand its genetic health risk report could potentially increase the company's market share and revenues.
The FDA clearance allows 23andMe to report additional genetic variants associated with higher cancer risk. This could potentially attract more customers seeking comprehensive genetic health risk reports, thereby increasing the company's market share and revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100